Research programme: spinal muscular atrophy gene therapy - Tapestry PharmaceuticalsAlternative Names: Spinal muscular atrophy gene therapy research programme - Tapestry Pharmaceuticals
Latest Information Update: 10 Aug 2005
At a glance
- Originator Tapestry Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Spinal muscular atrophy
Most Recent Events
- 10 Aug 2005 Discontinued - Preclinical for Spinal muscular atrophy in USA (unspecified route)
- 22 Jun 2005 Preclinical trials in Spinal muscular atrophy in USA (unspecified route)